The treatment administered orally is a micro-emulsion “water in oil”
composed of three lipids and a purified extract of nettle
September 15, 2014
Written by Armelle Bohineust , translated by D’un Renard
Allied to the CEA (French Atomic Energy and Alternative Energies Commission ), the French biotechnology company Medesis Pharma is developing a treatment to protect people exposed to radioactivity.
Soon a mean to protect the population against nuclear contamination, whether a Fukushima type or attack? This is the project of the French biotechnology company Medesis Pharma combined with the CEA.
They filed a joint European patent and develop products capable of extracting plutonium from infected persons.
The treatment is a microemulsion “water in oil” given orally, consisting of three specific lipids identified in research conducted between 1992 and 1997 on a purified extract of the antidiabetic plant, nettle.
Inhaled with an individual spraying inhaler, the product passes through the mucosa, joined the lymphatic and blood circulation and penetrates all cells.
Administered for several weeks Aonys is gradually decreasing the amount of radioactive toxins in the body.
Established in 2003 near Montpellier, and also based in Montreal, Canada where it has installed some of its research team in the Neomed Institute, Medesis began working with CEA in 2004 and has already raised 15 million euros.
Biotech plans to raise additional funds to launch the development of a pharmaceutical product removing plutonium from the body. It could be commercialized by 2017 and will be followed by products for cesium and uranium, says Jean-Claude Maurel, President Medesis. Targeting the US market, where they are supposed to stockpile drugs to protect civilian populations living near nuclear power plants. “We just need a stock to cover the needs of the population within a radius of 30 km around the plant, which is the emergency accident evacuation zone.
For example, the area around the Bugey nuclear power plant in France encompasses 700,000 people, “says the founder of Medesis. The value of one million doses amounting to almost € 60 million, the company expects a strong increase in its turnover, estimated at “several hundred million” in the first two years marketing of this product. “We’ll be the first to launch such product of individual spray type for the removal of plutonium and cesium, but also uranium, for which no treatment exists to date,” explains Jean-Claude Maurel.
Using the same technology, which allows administering metal ions at very low doses, Medesis Pharma is developing treatments for neurodegenerative diseases such as Huntington’s disease.
End of 2014, the biotech will launch its Phase 2 clinical development of a product containing lithium, used to treat bipolar patients. “Another market of several hundred million euros”, according to Jean-Claude Maurel.
Source: Le Figaro (Economy)